{"doi":"10.1007/s13277-014-2799-7","title":"The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials","abstract":null,"journal":"Tumor Biology","year":2015,"id":638071,"datarank":0.41588830833596724,"base_score":2.772588722239781,"endowment":2.772588722239781,"self_citation_contribution":0.41588830833596724,"citation_network_contribution":0.0,"self_endowment_contribution":0.41588830833596724,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":15,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1657044,"name":"Xinlan Qu","orcid":null,"position":1,"is_corresponding":false},{"id":1657046,"name":"Boran Cheng","orcid":null,"position":2,"is_corresponding":false},{"id":401492,"name":"Yuanyuan Chen","orcid":"0000-0003-3047-6045","position":3,"is_corresponding":false},{"id":1657048,"name":"Zhenmeng Wang","orcid":null,"position":4,"is_corresponding":false},{"id":32625,"name":"Fangfang Chen","orcid":"0000-0002-0854-1667","position":5,"is_corresponding":false},{"id":943912,"name":"Bin Xiong","orcid":"0000-0003-3657-8405","position":6,"is_corresponding":false},{"id":364883,"name":"Yuan Fang","orcid":"0000-0002-9472-2703","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials","abstract":"Bevacizumab (Bev) combined with chemotherapy significantly improves progression-free survival (PFS) but not overall survival (OS) in patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). The efficacy and safety depend on the type of chemotherapy combined with Bev. We performed a meta-analysis of phase III trials to evaluate the efficacy and safety of Bev + standard chemotherapy for HER2-negative MBC. The Cochrane Central Register of Controlled Trials, the Cochrane databases, EMBASE, MEDLINE, and ClinicalTrials.gov were analyzed. The primary outcomes included PFS, OS, and toxicity. Event-based hazard ratios (HRs) and relative risks (RRs) were expressed with the 95% confidence intervals (CIs). Four randomized controlled trials consisting of 3082 patients were included. Bev + standard chemotherapy improved PFS (HR 0.70, CI 0.64-0.77, P = 0.000) but had no effect on OS (HR 0.92, CI 0.82-1.02, P = 0.119). Bev + chemotherapy increased the incidence of febrile neutropenia (RR 1.45, CI 1.00 to 2.09, P = 0.048), proteinuria (RR 11.68, CI 3.72-36.70, P = 0.000), sensory neuropathy (RR 1.33, CI 1.05-1.70, P = 0.020), and grade ≥3 hypertension (RR 13.94, CI 7.06-27.55, P = 0.000). No differences in efficacy were observed between Bev + paclitaxel and Bev + capecitabine (Cape), but Bev + Cape increased the incidence of neutropenia. Bev + standard chemotherapy improved PFS in HER2-negative MBC patients. No benefit in OS was observed. Bev + Cape and Bev + paclitaxel had similar treatment efficacy, but Bev + Cape had a higher incidence of neutropenia.","is_dataset_classified":null,"base_score":2.772588722239781,"endowment":2.772588722239781,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"25387808","pmcid":null,"openalex_id":"https://openalex.org/W2021111838","authors":[],"funders":[],"total_grants":0,"fwci":0.5562,"citation_percentile":0.48676471,"influential_citations":0,"citation_trend":[{"year":2015,"count":2},{"year":2016,"count":6},{"year":2017,"count":2},{"year":2020,"count":3},{"year":2021,"count":1},{"year":2022,"count":1}],"oa_status":"closed","license":"http://www.springer.com/tdm","oa_locations":[{"url":"http://link.springer.com/content/pdf/10.1007/s13277-014-2799-7.pdf","host_type":"publisher"},{"url":"http://link.springer.com/article/10.1007/s13277-014-2799-7/fulltext.html","host_type":"publisher"},{"url":"http://link.springer.com/content/pdf/10.1007/s13277-014-2799-7","host_type":"publisher"},{"url":"https://doi.org/10.1007/s13277-014-2799-7","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/25387808","host_type":"repository"}],"fields_of_study":["Cancer Treatment and Pharmacology","Colorectal Cancer Treatments and Studies","HER2/EGFR in Cancer Research"],"mesh_terms":["Bevacizumab","Capecitabine","Antineoplastic Combined Chemotherapy Protocols","Breast Neoplasms","Deoxycytidine","Female","Fluorouracil","Humans","Neutropenia","Randomized Controlled Trials as Topic","Treatment Outcome","Paclitaxel","Clinical Trials, Phase III as Topic","Disease-Free Survival","Receptor, ErbB-2","Erb-b2 Receptor Tyrosine Kinases","Antibodies, Monoclonal, Humanized"],"keywords":["Medicine","Internal medicine","Bevacizumab","Neutropenia","Oncology","Hazard ratio","Metastatic breast cancer","Breast cancer","Chemotherapy","Capecitabine","Relative risk","Progression-free survival","Cancer","Confidence interval"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T20:03:50.480122Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}